Genes which participate in IFN production (TLR7, MyD88, IRAK1, and IRF7) did not show any significant difference in their expression level prior to CH combination therapy, and their level at the clinical outcome (Figure 4A and 4B). Here, IRAK1 is linked to cyclic hematopoiesis.